Boston Therapeutics Completes Enrollment in Phase ll Clinical Trial to Evaluate PAZ320 in Patients With Type 2 Diabetes
June 22, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jun 22, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "The Company"), a developer of complex carbohydrates to treat diabetes...
Boston Therapeutics to Launch SUGARDOWN(R), a Non-Systemic Approach to Managing Blood Glucose, at the Endocrinology Annual Meeting
June 21, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jun 21, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to...
Boston Therapeutics Receives $500,000 Equity Investment
June 14, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jun 14, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to...
Boston Therapeutics Retains MZ Group as Its Investor Relations Advisor
June 11, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jun 11, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to treat diabetes...
Boston Therapeutics Secures DTC Eligibility
June 07, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Jun 7, 2012) - Boston Therapeutics, Inc. (OTCQB: BTHE) (OTCBB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrates to treat diabetes...
Boston Therapeutics Receives First Purchase Order From Advance Pharmaceutical
April 18, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Apr 18, 2012) - Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, today announced that it has received its first commercial purchase order...
Boston Therapeutics PAZ320 Interim Clinical Trial Safety Results
April 10, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Apr 10, 2012) - Boston Therapeutics, Inc. (BTHE) (OTCBB: BTHE), a developer of diabetes therapeutics, announced today no safety concerns from the interim data analysis...
Boston Therapeutics Launches SUGARDOWN(R) Publicity Campaign
April 06, 2012 08:21 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Apr 6, 2012) - Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, announced today that it has launched a publicity campaign to increase...
Boston Therapeutics Corporate Update
April 02, 2012 15:57 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Apr 2, 2012) - Boston Therapeutics Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, reviews the series of events that have led to the availability of its lead...
Boston Therapeutics Is Quoted as BTHE on the OTC Bulletin Board
March 22, 2012 07:00 ET
|
Boston Therapeutics, Inc.
MANCHESTER, NH--(Marketwire - Mar 22, 2012) - Boston Therapeutics, Inc. (OTCBB: BTHE), a developer of diabetes therapeutics, is pleased to announce that the Company's common stock was quoted on...